Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) has announced the appointment of Jeymi Tambiah, MB ChB, FRCS, MS, FAPCR, FFPM, as chief medical officer (CMO), and the retirement of the current CMO, Dr. Mark Kowalski.
Dr. Tambiah is a board-certified cardiothoracic surgeon physician scientist who practiced at Guys and St Thomas’ Hospitals prior to entering the biopharmaceutical industry in 2008. Dr. Tambiah brings more than 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.
In a statement, Dr. James A. Helliwell, CEO of Eupraxia, commented, “I am excited to welcome Dr. Tambiah at such a pivotal development stage for Eupraxia as we advance EP-104GI in Eosinophilic Esophagitis. His extensive development and leadership experience will help drive the late-stage development and expansion of our gastroenterology pipeline. Jeymi’s deep clinical, regulatory and operational experience adds additional core strength to Eupraxia’s executive leadership.”
Dr. Helliwell added, “I also want to thank Dr. Kowalski for his important contributions in helping bring the company to this clinical stage. On behalf of all of us, I want to thank him for his leadership and wish him the very best in his retirement and his support as a senior consultant through the transition.”
